T 0134/18 (Formulations of a SRC/ABL inhibitor / BRISTOL-MYERS SQUIBB) of 23.04.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T013418.20210423
- Date of decision
- 23 April 2021
- Case number
- T 0134/18
- Online on
- 30 April 2021
- Petition for review of
- -
- Application number
- 06769997.5
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- FORMULATIONS OF A SRC/ABL INHIBITOR
- Applicant name
- Bristol-Myers Squibb Holdings Ireland
- Opponent name
- Aechter, Bernd
Fresenius Kabi Deutschland GmbH
Generics [UK] Limited - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 113(1) (2007)European Patent Convention Art 56 (2007)European Patent Convention Art 100(a) (2007)
- Keywords
- Right to be heard - substantial procedural violation (no)
Inventive step - (no) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.
3. Appellant's 3 request for a refund of the appeal fee is refused.